Waivers of informed consent in research with competent participants and the Declaration of Helsinki
European Journal of Clinical Pharmacology · 2023-04 · 79 (4) · 575-578
DOI: 10.1007/s00228-023-03472-w ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 08.03.2023. Verfasst von Rafael Dal-Ré. Beteiligte Einrichtung: Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid, Avda Reyes Católicos 2, 28040, Madrid, Spain. r…. Hauptthemen laut MEDLINE: Helsinki Declaration, Informed Consent. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The World Medical Association started revisions to the Declaration of Helsinki in 2022 and it will have to address numerous issues that have arisen in research ethics since the last 2013 revision [1]. In the face of critical issues that have surfaced during the COVID-19 pandemic, less salient but nevertheless critically important issues may go unnoticed. One of these concerns is the conditions under which it is ethically permissible to modify or waive written informed consent in research with competent participants. The Declaration of Helsinki recognizes that there are circumstances in which it is permissible for individuals who do not themselves provide informed consent to participate in research. In research with persons who are incapable giving informed consent (e.g., children, dementia patients), investigators must seek written informed consent from the legally authorized representatives. In trials conducted with individuals that are incompetent for a limited period of time (e.g., hospitalized COVID-19 intubated patients) a deferred consent must be sought: when legal representative is available, their written consent must be followed by the participant’s written consent to remain in the trial once he/she can provide it. However, the Declaration of Helsinki, currently recognizes no exception to the requirement that competent individuals must provide informed consent to participate in medical research [1]. As a result, the guidance in the Declaration of Helsinki diverges from the Council for International Organizations of Medical Sciences (CIOMS) guidelines [2] −prepared in collaboration with the World Health Organization and is the ethics code commonly followed in lowand middle-income countries−, that allow for the modification and waiver of written informed consent if the research fulfills three conditions: a) it would not be feasible or practicable without the modification or waiver of informed consent; b) has important social value; and c) poses no more than minimal risk to participants. For research involving humans, the regulations of Australia [3], Canada [4], and the USA [5] ask for the fulfillment of several requirements, the two critical ones are the impracticability of the research and that it does not involve more than minimal risk (Table 1). The research must always be approved by the relevant research ethics committee [2–5]. Provisions for a waiver of informed consent are common in certain types of research. Thus, for example, depending on the unit of randomization, randomized controlled trials (RCTs) can randomize individuals or clusters (groups) of persons. While the former is the classical RCT useful to evaluate almost all type of interventions, the latter are increasingly common beyond the typical RCTs assessing health promotion and educational interventions. The possibility of conducting ethically-sound cluster RCTs with a waiver or alteration of written consent is well established: the interventions and data collection should pose no more than minimal risk and the research will be unfeasible without a waiver or alteration of informed consent [6]; conversely, a similar approach for certain types of individual-level RCTs is less accepted [7] −although both types of trials share the same ethical requirements. Thus, for example, the EU regulation on clinical trials with drugs accepts a modified (‘simplified’) consent for low-risk cluster RCTs but not for low-risk trials randomizing individuals [8]; the same approach is proposed for legislative changes for clinical trials with medicines and medical devices in the UK [9]. Certain type of participant-level comparative effectiveness RCTs in competent individuals can be facilitated by * Rafael Dal-Ré rafael.dalre@quironsalud.es
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid, Avda Reyes Católicos 2, 28040, Madrid, Spain. rafael.dalre@quironsalud.es.
ORCID-Profile: Rafael Dal-Ré
Zitieren
APA
Dal-Ré, R. (2023). Waivers of informed consent in research with competent participants and the Declaration of Helsinki. European Journal of Clinical Pharmacology, 79(4), 575-578. https://doi.org/10.1007/s00228-023-03472-w
Vancouver
Dal-Ré R. Waivers of informed consent in research with competent participants and the Declaration of Helsinki. European Journal of Clinical Pharmacology. 2023;79(4):575-578. doi:10.1007/s00228-023-03472-w
BibTeX
@article{DalR2023,
author = {Dal-Ré, Rafael},
title = {Waivers of informed consent in research with competent participants and the Declaration of Helsinki},
journal = {European Journal of Clinical Pharmacology},
year = {2023},
volume = {79},
number = {4},
pages = {575--578},
doi = {10.1007/s00228-023-03472-w}
}
EUVIMED